Mizuho analyst Salim Syed raised the firm’s price target on BridgeBio to $50 from $29 and keeps a Buy rating on the shares. The analyst increased non-risk-adjusted peak sales for acoramidis from $2.0B to $2.5B following the positive results from the Phase 3 trial in ATTR-CM. The firm also increased its probability of success for acoramidis from 30% to 75% as it believes regulatory risk is relatively mitigated post the Phase 3 results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BBIO:
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio downgraded to Hold on full valuation at Jefferies
- BridgeBio downgraded to Hold from Buy at Jefferies
- BridgeBio (NASDAQ:BBIO) Skyrockets on Promising Data in Heart Disease
- BridgeBio reports results from Phase 3 study of ATTR-CM